Advanced Cell Technology, Inc. (ACTC.OB) Closes 2010 with $25 Million Stock Purchase Agreement
What a year it has been for Advanced Cell Technology, Inc. (“ACT”). Developments really kicked it in gear during the final quarter of 2010, ending the year with a host of positive news and the strength of a $25 million stock purchase agreement to continue to shore up the Company’s finances. The Company has been in the forefront of the biotechnology world with its FDA clearance to use embryonic stem cells for Stargardt’s Macular Dystrophy and has gone from being a quiet developmental biotech to the center stage of the industry. Reinforcing this idea, Dr. Robert Lanza, Advanced Cell’s Chief…